Spain
AELIX Therapeutics, founded in 2014, is a clinical-stage biotechnology company headquartered in Barcelona, Spain. Known for its slogan, "Developing novel vaccines to cure HIV infection," AELIX is at the forefront of creating a therapeutic HIV vaccine as part of cure/eradication strategies. The company is a spin-off from HIVACAT, a public-private consortium known for pioneering research in HIV.
AELIX holds an exclusive worldwide license for the development and commercialization of the HTI immunogen, a critical asset in their innovative efforts. Operating within the Biotechnology, Health Care, and Health and Wellness industries, AELIX represents an attractive investment opportunity for those interested in breakthrough health solutions.
The company's last investment round was a $2.19M Late VC investment on 01 September 2021. Despite the lack of disclosed investors for this round, the demonstrated commitment towards developing an HIV vaccine places AELIX in a promising light for future investment scenarios.
